Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

ALS

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in ALS

5 stories · every one Fact-Checked
Pridopidine early ALS findings and PREVAiLS Phase 3 clinical trial enrollment updateClinical TrialsPrilenia Reports Functional and Survival Signals for Pridopidine in ALSPrilenia Therapeutics and Ferrer reported exploratory functional, respiratory, and survival findings associated with pridopidine in 36 participants with early ALS.28 Oct 2026 · 4 min read
Fact-Checked
NX210c Phase 2 SEALS trial shows reduced ALSFRS-R functional decline in amyotrophic lateral sclerosisClinical TrialsNX210c Phase 2 ALS Trial Shows Reduced Functional DeclineAxoltis Pharma reports topline Phase 2 SEALS results for NX210c in ALS. Although the primary endpoint was not met, post-hoc analyses showed slower ALSFRS-R decline versus placebo, with…16 Sep 2026 · 4 min read
Fact-Checked
NRG5051 NLRX1-mediated mPTP mechanism for ALSResearchNRG5051 Targets mPTP Through Novel NLRX1 Mechanism in ALSNRG Therapeutics has disclosed a novel NLRX1-mediated mechanism through which NRG5051 inhibits the mitochondrial permeability transition pore (mPTP), alongside preclinical data showing anti-inflammatory and neuroprotective effects in ALS…25 Aug 2026 · 3 min read
Fact-Checked
A blue wall exterior with a left-pointing arrow sign and metal railings.Clinical TrialsAB Science Discontinues Three Masitinib Trials to Prioritize ALS Phase III and AML ProgramAB Science has halted three masitinib trials in mast cell activation syndrome, mastocytosis, and multiple sclerosis, redirecting focus to ALS and AML programs.11 Jul 2026 · 3 min read
Fact-Checked
Focused athlete in wheelchair fencing gear, showcasing strength and determination.Health TidingsCoya Therapeutics Secures FDA Fast Track Tag for COYA 302 in ALSThe FDA granted Fast Track Designation to Coya Therapeutics’ investigational ALS therapy COYA 302, a biologic combination designed to enhance regulatory T cell function and reduce inflammation.13 May 2026 · 2 min read
Fact-Checked
Page 1 of 1